We were proud to present a program that highlighted some of the cutting-edge cancer research taking place across Oxford. Our sessions this year explored research within the themes of Early Detection and Immuno-Oncology, New to Oxford, and Digitally-Enabled Research, as well as a session dedicated to patient and public involvement in research.
We were also honoured to welcome Professor Trevor Graham, Director of the Centre for Evolution and Cancer at The Institute of Cancer Research, as our keynote speaker. His interdisciplinary lab combines mathematical modelling and molecular biology to study cancer evolution, with a translational focus spanning early detection to treatment of metastases, particularly in colorectal cancer.
Congratulations to our poster prize winner - Daniele Cotton, for poster Single-Cell Functional Biology in the Tumour-Bone Microenvironment: identification of individual prostate cancer cells with high metastatic potential. Congratulations, too, to our runner up, Alice Beard - for poster: Identification of novel regulators of IFN-I in cancer (pictured).
Reflecting on the past year, Mark Middleton, Co-Director of Oxford Cancer commented:
'We take immense pride in the progress made by Oxford’s cancer research community and the role that Oxford Cancer has played in facilitating your impactful and headline-grabbing research. Among this year’s achievements: the MyMelanoma trial became the largest study of its kind through partnership with NHS Digitrials; we launched two new Centres of Research Excellence focused on Liver and Oesophagogastric cancers to accelerate research in two cancers of unmet need; and securing external funding for precision prevention programmes in colorectal, ovarian, lung and cervical cancers.'
Tim Elliott, Co-Director of Oxford Cancer added:
'Another major milestone to note is the recent launch of our £50 million partnership with GSK to explore the potential of cancer prevention through immunotherapy. The GSK-Oxford Cancer Immuno-Prevention Programme, led by Professor Sarah Blagden, unites expertise from four University departments and builds on Oxford’s exceptional track record in vaccine development. As Professor Irene Tracey, Vice-Chancellor of the University of Oxford, stated: ‘This partnership represents a step forward in cancer research.’
You can read more about these achievements on our news pages.
